Literature DB >> 23906440

Semicircular canal dehiscence: frequency and distribution on temporal bone CT and its relationship with the clinical outcomes.

Muzaffer Elmali1, Ahmet Veysel Polat, Harun Kucuk, Sinan Atmaca, Ahmet Aksoy.   

Abstract

PURPOSE: In this study, we aimed to investigate the frequency of SCD and its distribution and relationship with clinical outcomes on thin-section CT of the temporal bone.
MATERIALS AND METHODS: Digital temporal bone CT images of 850 consecutive patients (1700 temporal bone CTs, 5100 SCs) who presented with a range of complaints such as vertigo, deafness, ear pain, fullness, and discharge between January 2008 and December 2011 were re-evaluated. Axial and oblique coronal reconstruction images of the temporal bone were made with a reconstruction thickness of 0.5mm. Additionally, superior SC was evaluated in two perpendicular planes.
RESULTS: Out of 850 patients, 70 had completely normal temporal bone CT. Ninety-three patients had at least one SCD. In the temporal bone-based evaluation, 119 (26 bilateral, 67 unilateral) of 1700 temporal bones (7%) showed dehiscence. The SC-based evaluation revealed 125 SCD (2.5%) in 5100 SCs. The total number and rates of SCD were as follows: superior 103 (82.4%), posterior 13 (10.4%), and lateral nine (7.2%). Twenty of the 93 patients with SCD (21.5%) revealed no other findings on their temporal bone CTs. We determined a significant correlation between vestibular complaints, conductive hearing loss and SCD but there was no correlation between mixed, sensorineural hearing loss and SCD.
CONCLUSION: We determined the frequency of SCD in 11% of patients and 7% of temporal bones. With regards to the distribution, the superior SC showed the highest dehiscence rate (82.4%). We found a significant correlation between vestibular symptoms, conductive hearing loss and SCD.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Canal dehiscence, third window lesions; Hearing loss; Superior semicircular canal dehiscence; Temporal bone CT

Mesh:

Year:  2013        PMID: 23906440     DOI: 10.1016/j.ejrad.2013.06.022

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  7 in total

1.  Cochlear implantation in patients with definite Meniere's disease.

Authors:  Nils Kristian Prenzler; Eva Bültmann; Alexandros Giourgas; Melanie Steffens; Rolf Benedikt Salcher; Stefan Stolle; Anke Lesinski-Schiedat; Thomas Lenarz; Martin Durisin
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-10-25       Impact factor: 2.503

2.  Positive perilymph fistula test with semicircular canal dehiscence from cholesteatoma.

Authors:  Ming-Chih Hsieh; Chen Chi Wu; Shih-Hao Wang
Journal:  CMAJ       Date:  2019-01-28       Impact factor: 8.262

3.  Comorbidities confounding the outcomes of surgery for third window syndrome: Outlier analysis.

Authors:  P Ashley Wackym; Heather T Mackay-Promitas; Shaban Demirel; Gerard J Gianoli; Martin S Gizzi; Dale M Carter; David A Siker
Journal:  Laryngoscope Investig Otolaryngol       Date:  2017-08-22

4.  Bilateral superior semicircular canal dehiscence: bilateral conductive hearing loss with subtle vestibular symptoms.

Authors:  Diogo Pereira; Abílio Leonardo; Delfim Duarte; Nuno Oliveira
Journal:  BMJ Case Rep       Date:  2020-03-12

Review 5.  Recent surgical options for vestibular vertigo.

Authors:  Stefan Volkenstein; Stefan Dazert
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2017-12-18

6.  Third Window Syndrome: Surgical Management of Cochlea-Facial Nerve Dehiscence.

Authors:  P Ashley Wackym; Carey D Balaban; Pengfei Zhang; David A Siker; Jasdeep S Hundal
Journal:  Front Neurol       Date:  2019-12-13       Impact factor: 4.003

7.  Longitudinal Cognitive and Neurobehavioral Functional Outcomes Before and After Repairing Otic Capsule Dehiscence.

Authors:  P Ashley Wackym; Carey D Balaban; Heather T Mackay; Scott J Wood; Christopher J Lundell; Dale M Carter; David A Siker
Journal:  Otol Neurotol       Date:  2016-01       Impact factor: 2.311

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.